Oak Thistle LLC Has $824,000 Stock Holdings in Avantor, Inc. (NYSE:AVTR)

Oak Thistle LLC reduced its position in shares of Avantor, Inc. (NYSE:AVTRFree Report) by 5.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 39,085 shares of the company’s stock after selling 2,099 shares during the quarter. Oak Thistle LLC’s holdings in Avantor were worth $824,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. grew its holdings in Avantor by 2.7% during the 2nd quarter. American Century Companies Inc. now owns 1,641,764 shares of the company’s stock worth $34,805,000 after acquiring an additional 42,868 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Avantor by 1.7% in the second quarter. Envestnet Asset Management Inc. now owns 1,097,671 shares of the company’s stock worth $23,271,000 after purchasing an additional 18,672 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Avantor by 8.6% in the second quarter. Dimensional Fund Advisors LP now owns 4,434,195 shares of the company’s stock worth $94,018,000 after purchasing an additional 350,247 shares during the last quarter. Sargent Investment Group LLC acquired a new stake in Avantor in the second quarter valued at $338,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in Avantor by 4.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 25,440 shares of the company’s stock worth $539,000 after purchasing an additional 1,119 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Price Performance

AVTR stock opened at $21.82 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The company’s 50-day moving average is $21.49 and its 200-day moving average is $23.36. The stock has a market capitalization of $14.85 billion, a PE ratio of 47.43, a price-to-earnings-growth ratio of 2.75 and a beta of 1.28. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AVTR shares. UBS Group decreased their price target on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Wells Fargo & Company decreased their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Finally, Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.69.

Check Out Our Latest Report on AVTR

About Avantor

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Featured Stories

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTRFree Report).

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.